Biocon Biologics to get Biologics licence application for cancer & eye disease medication

Biocon Biologics Ltd (a subsidiary of Biocon Ltd) and Mylan (a subsidiary of Viatris Inc.) have been further informed by United States Food & Drug Administration (USFDA) regarding the deferral of the action on Biologics licence application (BLA) for MYL-1402O, a proposed biosimilar to Avastin® (Bevacizumab). 

Bevacizumab, sold under the brand name Avastin, is used to treat a number of cancers and specific eye diseases. There is a need for the inspection of the manufacturing facility before the completion of the application as per the current review process. However, due to the COVID-19 situation, the authorities have not been able to perform the inspection in the current review cycle. The company awaits the dates for the inspection of the manufacturing facility in order to complete the application process as soon as possible. 

Meanwhile, the company has also informed that it has expanded its generic formulations portfolio with the launch of Tacrolimus capsules in the US.  

For more information, click here: 

https://www.dsij.in/DSIJArticleDetail/ArtMID/10163/ArticleID/16285/Biocon-gains-on-launching-immunosuppressant-in-US 

This throws light on Biocon's relentless pursuit of its mission to make affordable healthcare accessible. 

Biocon Ltd is a global pharmaceutical company, which aims to reduce the therapy costs of chronic diseases like autoimmune, diabetes, and cancer.  

At 1.05 pm on Tuesday, the stock of Biocon Biologics Ltd was trading at Rs 464.14, down by 0.35 per cent. It has A 52-week high of Rs 487.70 and an intraday high of Rs 475.75 on BSE.